Health ❯ Public Health ❯ Obesity

Weight Management

GLP-1 Drugs Medications Pharmaceuticals Weight-loss Drugs Prehabilitation BMI Measurement NHS Services Mounjaro Mindfulness Weight Loss Injections Treatment Strategies Medication Access Cravings Semaglutide Medication Use GLP-1 Medications NHS Policies Prescription Medications Drug Accessibility Personalized Medicine Weight-Loss Injections Anti-Obesity Medications Dietary Drugs Impact on Industries Pharmaceutical Interventions Clinical Implications Medications for Obesity Weight Loss Treatments Healthcare Services Weight Loss Drugs

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Phase 3 trials are set to begin this quarter following 48-week topline data showing large placebo-adjusted weight loss.

Trump Cites 'Very Fat' Friend's Ozempic Story to Decry Price Gap

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

U.S. Obesity Rate Drops to 37% as GLP-1 Use Surges, Gallup Finds